1. Home
  2. ONC
  3. ONC News

Latest BeiGene Ltd. American Depositary Shares (ONC) News on August 23, 2025

BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)
ONC

Simply Wall St.

a day ago

BRUKINSA Tablet Approval Could Be a Game Changer for BeOne Medicines (ONC)

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications
ONC

Business Wire

2 days ago

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth
ONC

Investor's Business Daily

8 days ago

This Medical Stock With Blockbuster Cancer Drug Clears Entry Amid 923% Earnings Growth

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine
ONC

Investor's Business Daily

8 days ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
ONC

Business Wire

2 months ago

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®
ONC

Business Wire

2 months ago

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

Exploring US High Growth Tech Stocks To Watch In June 2025
ONC

Simply Wall St.

2 months ago

Exploring US High Growth Tech Stocks To Watch In June 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025
ONC

Business Wire

2 months ago

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications
ONC

Business Wire

2 months ago

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
ONC

Business Wire

2 months ago

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

BeOne Medicines And 2 Stocks That May Be Undervalued By The Market
ONC

Simply Wall St.

2 months ago

BeOne Medicines And 2 Stocks That May Be Undervalued By The Market

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple
ONC

Investor's Business Daily

3 months ago

Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025
ONC

Business Wire

3 months ago

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
ONC

Business Wire

3 months ago

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

ONC

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Premarket Tuesday

ONC

MT Newswires

3 months ago

Sector Update: Health Care

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology
ONC

Business Wire

3 months ago

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

ONC

MT Newswires

3 months ago

BeiGene Says EU Panel Recommends Tevimbra as Treatment for Nasopharyngeal Cancer

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
ONC

Business Wire

3 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

Exploring US High Growth Tech Stocks In May 2025
ONC

Simply Wall St.

3 months ago

Exploring US High Growth Tech Stocks In May 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
ONC

Business Wire

3 months ago

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies
ONC

Simply Wall St.

3 months ago

BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
ONC

Business Wire

3 months ago

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
ONC

Business Wire

3 months ago

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
ONC

The Wall Street Journal

3 months ago

Trump's Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
ONC

Simply Wall St.

3 months ago

BeiGene First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
ONC

Simply Wall St.

3 months ago

Earnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential
ONC

Insider Monkey

3 months ago

BeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...
ONC

GuruFocus.com

3 months ago

BeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...

ONC

MT Newswires

3 months ago

RBC Trims Price Target on BeiGene to $311 From $312, Keeps Outperform Rating

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics
ONC

Zacks

4 months ago

Compared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key Metrics

ONC

MT Newswires

4 months ago

Sector Update: Health Care Stocks Advance Pre-Bell Wednesday

ONC

MT Newswires

4 months ago

BeiGene Swings to Q1 Adjusted Earnings, Revenue Increases; 2025 Revenue Outlook Reiterated

BeiGene Announces First Quarter 2025 Financial Results and Business Updates
ONC

Business Wire

4 months ago

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
ONC

Business Wire

4 months ago

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

3 Stocks That Could Be Trading Below Their Estimated Fair Value
ONC

Simply Wall St.

4 months ago

3 Stocks That Could Be Trading Below Their Estimated Fair Value

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?
ONC

Investor's Business Daily

4 months ago

Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?

Exploring 3 High Growth Tech Stocks In The US Market
ONC

Simply Wall St.

4 months ago

Exploring 3 High Growth Tech Stocks In The US Market

BeiGene to Announce First Quarter 2025 Financial Results on May 7
ONC

Business Wire

4 months ago

BeiGene to Announce First Quarter 2025 Financial Results on May 7

ONC

MT Newswires

5 months ago

RBC Initiates BeiGene at Outperform With $312 Price Target

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA
ONC

Simply Wall St.

5 months ago

BeiGene (NasdaqGS:ONC) Gains 32% In A Quarter Amid Positive EMA Opinion On TEVIMBRA

BeiGene halts ociperlimab amid poor Phase III trial predictions
ONC

Clinical Trials Arena

5 months ago

BeiGene halts ociperlimab amid poor Phase III trial predictions

ONC

MT Newswires

5 months ago

BeiGene to Discontinue Potential Lung Cancer Treatment Study

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
ONC

Business Wire

5 months ago

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

ONC

MT Newswires

5 months ago

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value
ONC

Simply Wall St.

5 months ago

Driven Brands Holdings Among 3 Stocks Priced Below Estimated Fair Value

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
ONC

Business Wire

5 months ago

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Exploring 3 High Growth Tech Stocks In The US Market
ONC

Simply Wall St.

5 months ago

Exploring 3 High Growth Tech Stocks In The US Market

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors
ONC

Benzinga

5 months ago

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors

ONC

MT Newswires

6 months ago

Beigene Insider Sold Shares Worth $2,073,826, According to a Recent SEC Filing

ONC

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Zymeworks Inc Earnings Call

ONC

MT Newswires

6 months ago

Beigene Insider Sold Shares Worth $24,674,638, According to a Recent SEC Filing

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction
ONC

Simply Wall St.

6 months ago

FDA Approval For BeiGene (NasdaqGS:ONC) TEVIMBRA In ESCC Shows 34 Percent Death Risk Reduction

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer
ONC

Pharmaceutical Technology

6 months ago

FDA approves BeiGene’s Tevimbra plus chemo for oesophageal cancer

ONC

MT Newswires

6 months ago

BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
ONC

Business Wire

6 months ago

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

ONC

MT Newswires

6 months ago

Beigene Insider Sold Shares Worth $331,375, According to a Recent SEC Filing

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025
ONC

Insider Monkey

6 months ago

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results
ONC

Simply Wall St.

6 months ago

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?
ONC

Insider Monkey

6 months ago

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
ONC

Simply Wall St.

6 months ago

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ONC

Zacks

6 months ago

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

ONC

MT Newswires

6 months ago

Sector Update: Health Care Stocks Decline Premarket Thursday

ONC

MT Newswires

6 months ago

BeiGene Ltd BeiGene Q4 Net Loss Narrows, Revenue Rises; 2025 Revenue Guidance Set

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
ONC

Business Wire

6 months ago

BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

BeiGene to Present at Upcoming Investor Conferences
ONC

Business Wire

6 months ago

BeiGene to Present at Upcoming Investor Conferences

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50
ONC

Investor's Business Daily

6 months ago

These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50

ONC

MT Newswires

6 months ago

BeiGene Insider Sold Shares Worth $12,485,045, According to a Recent SEC Filing

US Stocks Trading Below Estimated Value In February 2025
ONC

Simply Wall St.

6 months ago

US Stocks Trading Below Estimated Value In February 2025

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
ONC

Zacks

6 months ago

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

High Growth Tech Stocks in the United States to Watch
ONC

Simply Wall St.

6 months ago

High Growth Tech Stocks in the United States to Watch

HRMY or ONC: Which Is the Better Value Stock Right Now?
ONC

Zacks

6 months ago

HRMY or ONC: Which Is the Better Value Stock Right Now?

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
ONC

Business Wire

6 months ago

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?
ONC

Simply Wall St.

6 months ago

Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?

ONC

MT Newswires

7 months ago

Beigene Insider Sold Shares Worth $9,424,955, According to a Recent SEC Filing

ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo
ONC

Clinical Trials Arena

7 months ago

ImmunityBio and BeiGene partner on Phase III trial of NSCLC treatment combo

ONC

MT Newswires

7 months ago

ImmunityBio Partners With BeiGene to Conduct Phase 3 Trial of Lung Cancer Combination Therapy

Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value
ONC

Simply Wall St.

7 months ago

Discover 3 US Stocks Including Microchip Technology That May Be Trading Below Estimated Fair Value

Exploring High Growth Tech Stocks in January 2025
ONC

Simply Wall St.

7 months ago

Exploring High Growth Tech Stocks in January 2025

When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)?
ONC

Simply Wall St.

7 months ago

When Can We Expect A Profit From BeiGene, Ltd. (NASDAQ:ONC)?

BeiGene Stock Meets 80-Plus RS Rating Benchmark
ONC

Investor's Business Daily

7 months ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?
ONC

Zacks

7 months ago

BeiGene (ONC) Moves 8.9% Higher: Will This Strength Last?

ONC

MT Newswires

7 months ago

Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
ONC

Business Wire

8 months ago

BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe

Share on Social Networks: